“Latest Stem Cells News”

Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported results from a planned interim analysis of the company’s multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. According to the interim analysis the safety profile was similar between the treatment and placebo arms.

Based on a composite efficacy endpoint assessing time to treatment failure (including major amputations, wound size and gangrene), Aastrom’s autologous vascular repair cells (VRCs) were more effective than placebo (P<0.05). Other clinically meaningful endpoints (e.g., major amputation rate, complete wound closure) approached but did not reach statistical significance at interim analysis. Forty-six critical limb ischemia (CLI) patients who had at least 6-month follow up, including 33 patients with 12-month follow up, contributed to the interim analysis.

Scientists have developed a new tool that illuminates connections between stem cells and cancer.
Researchers have been successful in breaking apart human prostate tissue, extract the stem cells in the tissue, and alter those cells genetically so that they spur cancer.

Many tissues contain pools of stem cells that replenish the tissue when it’s damaged or when changes take place. For example, stem cells in the skin produce new cells to replace those irreparably damaged by the sun, and stem cells in the breast create milk-producing cells when a woman is pregnant.

A characteristic of these stem cells is that they self-renew. This means that in addition to making cells with a specific function, they also make many new stem cells.

The team at Children’s Hospital Boston and the Harvard Stem Cell Institute were working with a new type of cell called induced pluripotent stem cells or iPS cells, which closely resemble embryonic stem cells but are made from ordinary skin cells.

In this case, they wanted to study a rare, inherited premature aging disorder called dyskeratosis congenita. The blood marrow disorder resembles the better-known aging disease progeria and causes premature graying, warped fingernails and other symptoms as well as a high risk of cancer.

One of the benefits of stem cells and iPS cells is that researchers can make them from a person with a disease and study that disease in the lab. Harvard’s Dr. George Daley and colleagues were making iPS cells from dyskeratosis congenita patients to do this (…)

Cells from people with premature aging disease get “younger” with the help of stem cell technology.

Premature aging is one of the most difficult-to-deal with conditions in the world. In addition to its physical consequences, its psychological impact is devastating on a person suffering from it. At this point, experts believe that the disease is caused by the fact that people predisposed to it have very short telomeres, which are repetitive stretches of DNA attached to the end of each chromosome in each cell featuring genetic material in the human body. As chromosomes multiply, the telomeres naturally get shorter, and scientists believe that this may be playing a role in aging.

Korean scientists are moving closer to cloning embryonic stem cells, the unprecedented breakthrough that their compatriot and disgraced scientist Hwang Woo-suk claimed to have achieved in 2004, only to have this disproved later.

Currently, a team at the Cha Medical Center is working on a project after getting state approval last year, while another team headed by professor Park Se-pill at Jeju National University is also set to begin research.
Park and his associates are awaiting final approval from the National Bioethics Committee.

“If the endorsement is made before June, we should be able to clone human embryonic stem cells sometime next year,” said Park, who extracted stem cells from human embryos, not cloned ones, in 2000.
“Our embryologists’ technology is leading on the global scene. Hence, I believe that Korean teams should be able to create cloned embryonic stem cells in the not-so-distant future,” he said.

Dr. Robert Johnson, MD, of Neurosurgical Associates of San Antonio, is presenting at the 5th Annual Stem Cell Summit in New York on February 16, 2010. Dr. Johnson will be presenting his most recent data proving the efficacy of point of care adult stem cell therapies in spine surgery. Point of care technology utilizes the patient’s own cells derived from bone marrow to inhibit bone growth in spinal fusion procedures. Dr. Johnson believes promoting cell therapy utilizing the patient’s own cells will change the future landscape of medicine.

“The use of autologous stem cells is revolutionizing medical care in both the prevention and treatment of spinal disorders,” said Johnson.